About | CSL Seqirus ConnectedCare

As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major
contributor to the prevention of influenza and a global partner in pandemic preparedness.
With state-of-the-art production facilities and leading R&D capabilities, we use egg, cell and
adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines.
In Australia, CSL Seqirus operates the only local manufacturing facility for seasonal and pandemic
influenza vaccines, and produces a range of unique medicines in the national interest, including antivenoms
and Q fever vaccines. We are also focused on addressing unmet needs by providing access to innovative and
differentiated in-licensed products. We're on the front line every day, working with our partners to deliver pioneering vaccine solutions to safeguard people and communities across the world.

Over 100 years of history

CSL Seqirus draws on over 100 years of experience in influenza vaccines. Since the beginning, CSL has been driven to save lives using the very latest technologies. Since then, we are proud that CSL Seqirus has grown into a global leader in influenza prevention.

1916

Commonwealth Serum Laboratories (CSL) is established to service the health needs of an infant Australian nation.

1919

When the deadly Spanish influenza pandemic strikes Australia, CSL responds rapidly with 3 million doses of a mixed bacterial vaccine.

1930

CSL releases a tiger snake antivenom, and goes on to develop antivenoms for Australia’s most venomous creatures.

1944

Production commences on an influenza virus vaccine and the first 1 million doses are supplied to Australian and British troops.

1951

WHO designates CSL as a Influenza Reference Laboratory to enhance Southern Hemisphere influenza surveillance.

1957

CSL responds quickly to the Asian influenza pandemic, producing 1.6 million doses of vaccine.

1968

As the Hong Kong influenza pandemic emerges, CSL produces 5 million doses of vaccine to protect the region.

1992

WHO designates CSL as an Influenza Collaborating Centre, strengthening its role in the global influenza network.

1994

CSL becomes a private company.

2002

CSL extends its influenza vaccine supply into the Northern Hemisphere.

2009

The organisation's rapid response to the H1N1 (swine flu) pandemic sees Australia become one of the first countries in the world to roll-out vaccine to its population, with stocks also donated to the WHO.

2015

CSL Seqirus, one of the largest influenza vaccine manufacturers in the world, is created when CSL acquires the Novartis' influenza vaccine business, combining it with bioCSL

2016

CSL Seqirus launches three new products and is well positioned for the future.

2018

CSL Seqirus secures FDA approval for next generation cell-based influenza vaccine manufacturing process.

1916

1919

1930

1944

1951

1957

1968

1992

1994

2002

2009

2015

2016

2018

Relentless drive to innovate

Innovation has been in the DNA of our parent company, CSL, since its beginning in 1916 and remains at the core of everything we do. We invest in research and development to focus on improving the effectiveness of current influenza vaccines and their manufacturing processes. We drive to explore novel formulations and alternate delivery technologies. Our mission is to maintain the highest level of preparedness for the next pandemic.

Updated March 2023. Date of Preparation: March 2023. AU-SEQ-23-0002